Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs A-dmDT390-anti-CD3bisFv immunotoxin (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Angimmune
- 15 Dec 2016 New trial record